MBq, and administered peptide mass averaged 43.2 ± 5.2 µg (n = 47) and 23.9 ± 5.7 µg (n = 127), respectively, using the EZAG and ITG generators. At dose expiration, 68 Ge breakthrough in the final product averaged 2.7 x 10 -7 % and 5.4 x 10 -5 % using the EZAG and ITG generators, respectively.
Introduction
Gallium-68-labeled somatostatin-receptor-targeted peptides, such as [ 68 (Virgolini, et al., 2010; Pettinato, et al., 2008; , but none are FDA-approved drug products in the USA.
These three targeting peptides vary slightly in amino acid sequence, resulting in variations in their receptor affinities and receptor-sub-type selectivity (Antunes, et al., 2007 ) , but all appear suitable for use in clinical imaging (Virgolini, et al., 2010) .
The Expanded Access IND (Investigational New Drug exemption) can be a mechanism for providing patient access to a drug product that is not FDA-approved, but that is clinically needed in treatment of a serious disease (21CFR312.305, 2013) . In response to a local clinical need to better define the location and extent of disease in neuroendocrine cancer patients who are candidates for multivisceral transplant (Mangus , el al., 2013) , a manual synthesis method was developed for on-demand preparation of the [ 68 Ga]Ga-DOTA-NOC peptide-chelate conjugate in a formulation suitable for intravenous administration, and an Expanded Access IND submitted to the FDA documenting the production procedure and the intended clinical use. We selected [ 68 Ga]Ga-DOTA-NOC because our clinical focus was to define extent of disease, and this agent offers affinity for a broader range of receptor sub-types than [ 68 Ga]Ga-DOTA-TOC or [ 68 Ga]Ga-DOTA-TATE ([ 68 Ga]Ga-DOTA-NOC exhibits significant affinity for ssrt3, sstr4, sstr5, as well as the sstr2 receptor sub-type most commonly expressed by neuroendocrine tumors) (Atunes, et al., 2007) .
We describe here our experience with manual radiochemical synthesis of [ 68 Ga]Ga-DOTA-NOC for clinical use under Expanded Access IND 117,255. The manual approach to synthesis was chosen because of the expected limited production volume, and the desire for a simple process that could be rapidly implemented and validated with minimal expense, since start-up and dose production costs needed to be recovered by charges to the patient. 68 Ga 3+ in either 1.5 mL 0.1M ultrapure HCl (fractionated elution of the EZAG generator), or 4.0-mL 0.05M ultrapure HCl (ITG generator, without fractionation). The eluate was buffered to pH ~4.8 by addition of ultrapure NaOAc and reacted with the DOTA-NOC conjugate (60-µg for the EZAG eluate; 30-µg for the ITG eluate) with heating for 10-minutes. For our initial manual synthesis method, the reaction mixture was heated in a sterile 15-mL polypropylene centrifuge tube using an Eppendorf Thermomixer (Figure 1) set at 80°C. Using the ITG generator we initially employed this same synthetic method, but then adapted our process to employ ITG's manually controlled Fluidic Module (Vis, et al., 2015; Tworowska et al., 2016; Roesch, 2012) for better radiation shielding during solution transfers. Required solution transfers in our process using the EZAG generator were simply made using syringes and needles (4-inch B Braun Medication Transfer Filter Straws and 3.5-inch 18-gauge spinal needles), employing tungsten syringe shields to minimize hand exposure. The ITG Fluidic Module (Vis, et al., 2015; Tworowska et al., 2016; Roesch, 2012) Pre-release product quality control procedures included: half-life measurement for confirmation of radionuclidic identity; pH measurement; ITLC assessment of radiochemical purity; endotoxin testing (Endosafe ® -PTS, Charles River Laboratories); and a bubble point measurement to confirm the integrity of the single-use sterile 0.2-µm filter employed for terminal product sterilization. The half-life determination was made using a radionuclide dose calibrator (Capintec CRC-55tW) to make eight timed measurements of 68 Ga radioactivity over a 7-minute period, calculating the corresponding half-life from the slope of the regression line in a spreadsheet plot of ln(radioactivity) vs. time (Apple iPad ® running Numbers ® application). The measured half-life was required to fall in the range of 64.6 -71.4 minutes. The ITLC determination of radiochemical purity employed ITLC-SG strips developed with 0.1M HCl to quantify levels of ionic 68 Ga, and ITLC-SG strips developed with 1:1 MeOH:1M NH 4 OAc to quantify colloidal 68 Ga-hydroxide plus ionic 68 Ga (Gallium Edotreotide Injection, 2010) . In process validation, the ITLC strips were analyzed with a Bioscan AR-2000 radiochromatogram scanner fitted with high-resolution collimator (Figure 3) . But, for speed and simplicity, our routine quality control instead employed a NaI(Tl) well scintillation counter to quantify radioactivity levels on the sectioned ITLC strip. For gamma counting, the ITLC-SG strip developed with 0.1M HCl was cut at the mid-point between the origin and solvent front, while the strip developed with 1:1 MeOH:1M NH 4 OAc was cut for counting at one-third the distance from the origin to the solvent front.
MATERIALS and METHODS

As
Retrospective analysis of each production batch included sterility testing, and measurement of 68 Ge breakthrough. Breakthrough was measured by NaI(Tl) scintillation counting of [ 68 Ga]Ga-DOTA-NOC dose samples at both 15-20 hours, and 48-96 hours, after dose preparation, thereby quantifying original 68 Ga, and breakthrough 68 Ge/ 68 Ga, respectively. (Beckman Gamma 8000 automatic gamma counter with 3-inch large-bore NaI(Tl) crystal. Counting window centered at 511 keV. 60-minute counting periods were employed for the final assay, since at the lowest observed breakthrough levels the sample count rates were at, or near, the background count rate.)
A more detailed description of the production processes employed with the EZAG and ITG generators, including SOPs and Batch Record documentation, is provided in the online Supplementary Material.
RESULTS AND DISCUSSION
Our objective was to reliably produce the [ 68 Ga]Ga-DOTA-NOC radiopharmaceutical for clinical use in accordance with the EANNMI procedure guidelines (Virgolini, et al., 2010) , while minimizing both start-up and recurring costs. While automated synthesis systems are commercially available for peptide labeling with 68 Ga, given the simplicity and scale of the required chemistry, our objectives were most effectively accomplished with the manual synthesis procedures described above.
The elution profile of the EZAG and ITG generators are similar, with nearly all the available 68 Ga delivered in ≤2 mL of the total 4-5 mL elution volume. We employed fractionated elution of the EZAG generator system to minimize introduction of trace metals into the [ 68 Ga]Ga-DOTA-NOC reaction mixture, allowing labeling with consistently high yields while avoiding pre-synthesis clean-up of the generator eluate (Di Pierro, et al., 2008; Schultz, et al., 2013; Eppard, et al., 2014) ]. Specifically, after discarding the generator void volume, we collected the next ~1.8-mL of EZAG generator eluate for synthesis, transferring 1.5-mL of that volume to the reaction mixture, and using the remainder for the regulatory-mandated half-life measurement (performed during the synthesis heating period), plus a subsequent measure of the level of 68 Ge breakthrough that was present in the reaction mixture. The generator void volume always proved stable over the 12-month period of generator use; however, void volume did vary slightly from generator-to-generator, making it critical to establish elution profile as part of the initial generator set-up testing if one expects to employ fractionated elution.
Since it does not employ a metal oxide stationary phase, the ITG generator provides an eluate with very low contamination by trace metals (Vis, et al., 2015; Tworowska et al., 2016; Roesch, 2012) . After pilot syntheses, we did not fractionate the ITG generator eluate, because we were able to obtain reliable product synthesis using the full 4-mL elution volume even employing a lower mass of the DOTA-peptide conjugate than used with the fractionated EZAG generator eluate (30-µg vs. 60-µg DOTA-NOC). In the case of product prepared with the ITG generator, the required half-life measurement was made using the final patient dose while awaiting completion of the endotoxin test.
The ITG Fluidic Module is designed to minimize worker hand exposure, while enabling efficient manual performance of the steps required in radiopharmaceutical synthesis (Vis, et al., 2015; Tworowska et al., 2016; Roesch, 2012 ). ITG's detailed operating procedure concludes with delivery of the 68 Ga-DOTA-peptide into a final product vial via in-line sterilizing filtration. However, to minimize revisions to the IND production protocol we had already established using the EZAG generator, upon switching to the ITG generator we continued to process the ethanol:saline eluate from solid-phase-extraction (i.e., the [ 68 Ga]Ga-DOTA-NOC intermediate product) without modification to our prior procedure. Thus, the ITG Fluidic Module was simply employed to remotely effect addition of reagents and generator eluate to the heated reaction vessel, and subsequent product loading to, and recovery from, the C18 SepPak ® cartridge. Thus, as implemented, our protocol always applied the terminal sterilizing filtration (Figure 2 ) to the fully formulated [ 68 Ga]Ga-DOTA-NOC product in 5% ethanol:saline. 68 Ga generators were employed in this period. Generator elution yields were higher with the ITG generator than the EZAG generator; and in both cases the elution yields were consistent with the manufacturer's specifications. The radiochemical purity of the [ 68 Ga]Ga-DOTA-NOC product was consistently high, averaging 99.2 ± 0.4% (Table 1) , and never approached our 92% lower limit. All doses passed retrospective 14-day USP sterility testing, and had endotoxin levels at <5 EU/mL. The quantity of DOTA-NOC in the administered doses (Table 1) was always in keeping with the European Association of Nuclear Medicine Procedure Guidelines recommendation of ≤50 µg (Virgolini, et al., 2010) . 68 Ge breakthrough in the [ 68 Ga]Ga-DOTA-NOC radiopharmaceutical (Table 1) was always far below the very conservative 0.001% upper limit (Virgolini, et al., 2010; Velikyan, et al., 2013) , regardless of generator manufacturer. Consistent with the manufacturers' generator specifications, 68 Ge breakthrough was higher with the ITG generator ( Table 1 ).
The C18 solid-phase extraction procedure used in [ 68 Ga]Ga-DOTA-NOC isolation provided a >100-fold reduction in the level of 68 Ge breakthrough carried through to the final product. For 44 doses produced using the EZAG generators we directly measured 68 Ge breakthrough in a residual sample of the fraction of generator eluate used in [ 68 Ga]Ga-DOTA-NOC synthesis, as well as in the final [ 68 Ga]Ga-DOTA-NOC product. 68 Ge breakthrough in the fractionated generator elute averaged 8.6 x 10 -5 ± 1.3 x 10 -4 % (median 4.2 x 10 -5 %), but dropped to 3.0 x 10 -7 ± 3.6 x 10 -7 % (median 1.9 x 10 -7 %) in the subsequent [ 68 (Figures 4 and 5) . The primary motivation for pursuing clinical [ 68 Ga]Ga-DOTA-NOC imaging via an Expanded Access IND was a critical local need for the best available approach to defining the extent of disease in patients with advanced neuroendocrine cancer who were being considered for multi-visceral organ transplantation (Mangus, et al., 2013) . PET/CT with [ 68 Ga]Ga-DOTA-NOC has also be quite useful in clinical evaluation of patients with either suspected neuroendocrine cancer, or a suspected neuroendocrine cancer recurrence, with the PET procedure often locating disease in patients for whom conventional 111 In-Octreoscan imaging and conventional radiographs were negative, but inconsistent with clinical presentation (Figure 5 ).
CONCLUSIONS
The manual [ 68 Ga]Ga-DOTA-NOC synthesis methods, whether implemented with the EZAG or ITG generators, have been convenient, reliable and robust in radiopharmaceutical production for clinical use. With reasonable measures to minimize introduction of unnecessary trace metals (use of ultrapure reagents, an effort to minimize reagent volumes, and fractionated elution of the generator), we consistently obtained high purity [ 68 Ga]Ga-DOTA-NOC while reliably remaining below the 50-µg limit for acceptable peptide mass (Virgolini, et al., 2010) , even using the EZAG generator without pre-synthesis purification of the 68 Ga 3+ . The Expanded Access IND has provided a valuable regulatory pathway for supplying this investigational drug, allowing [ 68 
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Supplementary data to this article, including detailed synthesis protocols and associated batch record sheets, can be found online at: *Maximum possible value, assuming the total DOTA-NOC mass employed in the synthesis remains present in the final product solution (i.e., assuming no mass loss in material transfers or in the purification of product by C18 solid-phase extraction).
